Core Viewpoint - Company is actively engaging with various institutional investors and has a diverse range of products across multiple sectors, indicating strong market interest and potential for growth [1] Business Overview - Company operates in four main business segments: 1. Industrial Testing Instruments, including helium mass spectrometers and leak detectors, primarily used in sectors like new energy and automotive [2] 2. Online Monitoring Instruments, focusing on environmental and industrial process monitoring, applicable in industries such as petrochemicals and metallurgy [2] 3. Laboratory Analytical Instruments, offering a wide range of products for life sciences and food testing [2] 4. Medical Instruments, with products like ultrasonic knives and blood dialysis devices, entering collective procurement in Guangdong [2] Product Applications - Company's leak detection technology is crucial for vacuum systems in nuclear fusion devices, ensuring operational safety and stability [3][4][5] - Various products, including helium mass spectrometers, are applicable in semiconductor manufacturing processes [7] R&D Progress - Development of blood dialysis equipment is on track, with prototypes undergoing third-party testing and expected to submit for regulatory approval by the end of 2025 [9] Financial Performance - For Q1 2025, company reported a main revenue of 134 million yuan, a year-on-year increase of 16.87%, with a net profit loss of 5.45 million yuan, but an improvement of 83.78% [10] - The company maintains a debt ratio of 37.31% and a gross margin of 50.04% [10] Market Sentiment - In the last 90 days, four institutions rated the stock, with three buy ratings and one hold rating, indicating positive market sentiment [11] - The average target price set by institutions is 22.6 yuan [11] Earnings Forecast - Earnings projections for 2025 to 2027 show a steady increase in net profit, with estimates ranging from 53 million to 124 million yuan by 2027 [12]

Core Viewpoint - The company is conducting a differentiated profit distribution plan for the fiscal year 2024, which includes a cash dividend of 1.00 RMB per 10 shares for all shareholders, excluding shares held in the repurchase account [5][6]. Group 1: Reasons for Differentiated Profit Distribution - The company approved a share repurchase plan on November 15, 2023, using its own funds to buy back shares for employee stock ownership plans or convertible bonds [2][3]. - The total amount for the share repurchase was adjusted from a minimum of 25 million RMB to a minimum of 55 million RMB and a maximum of 105 million RMB [3][4]. - The repurchase period was extended to May 14, 2025, allowing for a longer timeframe to complete the buyback [3][4]. Group 2: Details of the Profit Distribution Plan - The company will distribute cash dividends based on a total share capital of 134,708,490 shares, deducting the repurchased shares, resulting in a base of 125,322,411 shares for the dividend calculation [6]. - The total cash dividend to be distributed amounts to approximately 12,532,241.10 RMB, including tax [6]. - The company plans to maintain the per-share distribution ratio even if the total share capital changes due to various corporate actions [6]. Group 3: Calculation Basis for the Profit Distribution - The company calculated the ex-dividend reference price using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio) [7]. - The actual cash dividend per share for participating shareholders is approximately 0.10 RMB, with the ex-dividend reference price calculated to be around 21.90 RMB per share [9]. - The impact of the differentiated dividend on the ex-dividend reference price is less than 1%, indicating minimal effect on share value [9]. Group 4: Conclusion - The legal opinion confirms that the differentiated profit distribution complies with relevant laws and regulations, ensuring no harm to the company or its shareholders [7][8].

Core Insights - The 2024 revenue of the domestic instrument industry shows significant differentiation, with leading companies like Antu Bio achieving counter-cyclical growth while others face challenges due to market contraction and cost pressures [2][4] Group 1: Revenue and Income Disparities - The income of executives in the instrument sector has widened significantly compared to last year, primarily driven by high dividends [4] - Antu Bio's chairman, Miao Yongjun, is the only executive with an income exceeding 100 million yuan, with 99% of his income coming from dividends [4] - The dividend payout ratio for Antu Bio is 60.28% of net profit, while Tailin Bio has an even higher ratio of 91.94%, raising concerns about sustainable development [4] Group 2: Growth Drivers and Market Challenges - The biopharmaceutical supply chain and overseas markets are identified as core growth drivers, with Antu Bio's overseas revenue increasing by 36.25% year-on-year and Wanyi Technology achieving a remarkable 447% growth [4] - Traditional sectors like environmental monitoring and industrial process analysis are under severe pressure, as evidenced by the declining income of Xuedilong's chairman, which fell from 140 million yuan in 2022 to 110 million yuan in 2023 [5] Group 3: Cost Pressures and Profitability - Cost pressures are intensifying, squeezing net profit margins across the industry, with Tailin Bio facing significant profit margin erosion due to raw material price increases and price wars [6] - Despite a 15.01% year-on-year revenue growth, Lihua Technology experienced a decline in net profit due to rising costs and increased expenses [6] - Companies like Nanwei Technology have successfully implemented quality improvement and efficiency enhancement measures, restoring growth in core business areas while controlling expenses [6] Group 4: Executive Compensation Trends - The average pre-tax salary of executives has decreased to approximately 860,000 yuan, down from 1.2 million yuan last year, reflecting cost-cutting measures amid profit pressures [9] - The compensation structure for executives in the instrument industry is evolving, emphasizing the importance of strategic transformation, industry upgrades, and cost management [9]

Core Viewpoint - The article highlights the contrasting trends in employee changes among 44 listed instrument companies in China for 2024, indicating a split between companies expanding their workforce and those reducing it due to revenue pressures [1][5][10]. Group 1: Overall Trends - The overall trend shows a slight increase in employee numbers among listed instrument companies, with 24 companies expanding their workforce compared to 20 companies reducing it [5][6]. - Mindray Medical leads with a total of 21,667 employees, reflecting a 20.08% increase, driven by international expansion and digital transformation [5][6]. - Nanwei Technology shows a significant employee increase of 56.60%, attributed to its acquisition of shares in Fuli Instruments and expansion in high-margin product lines [5][6]. Group 2: Employee Reductions - 20 companies experienced varying degrees of layoffs, with HeXin Instruments seeing a drastic reduction from 684 to 276 employees, a nearly 60% drop [6][10]. - Other companies with significant layoffs include Wanyi Technology, JuGuang Technology, and Blue Shield Technology, indicating a strong correlation between workforce adjustments and revenue pressures [6][10]. Group 3: R&D Investment - Mindray Medical not only leads in total employees but also has a R&D team of 5,259, accounting for nearly 25% of its workforce, with an 18.85% increase in R&D personnel [7][10]. - Nanwei Technology's R&D personnel increased by 37.14%, with R&D investment rising by 25.84%, reflecting its commitment to high-precision material development [7][10]. - Other companies like Puyuan Precision Electric and Sand Technology also reported over 10% increases in R&D personnel, indicating active investment in new technologies [7][10]. Group 4: Industry Cycle Reflection - The changes in personnel structure reflect the development stages of various sub-industries, with life science instrument companies facing downward pressure due to market demand shifts and cost-cutting policies [9][10]. - In contrast, optical instruments and environmental monitoring companies are more active, leveraging new business opportunities and technological breakthroughs [9][10]. - The ongoing competition for high-quality R&D talent is expected to intensify as companies respond to technological innovation and domestic substitution trends [10].

Summary of Wanyi Technology Conference Call Company Overview - Wanyi Technology is undergoing a strategic transformation from traditional industrial environmental products to the semiconductor and industrial sectors, while actively developing medical instruments such as ultrasonic scalpels and blood dialysis machines, with the ultrasonic scalpel already entering centralized procurement, showcasing its potential for diversified development [2][3][4] Key Business Segments - The company has four main product lines: 1. **Industrial Intelligent Products**: Includes helium mass spectrometers, airtightness testers, and vacuum leak detection systems, primarily focused on the new energy sector and expanding into semiconductors [3] 2. **Industrial Environmental Products**: Focuses on environmental monitoring, transitioning towards semiconductor and industrial applications [3] 3. **Analytical Instruments**: Offers a comprehensive product line in the domestic market, including ion chromatography, gas chromatography, and liquid chromatography, serving universities, research institutions, and the food and agriculture sectors [3] 4. **Medical Instruments**: Developing blood dialysis machines and ultrasonic scalpels, with the latter having received Class III medical device certification and entering centralized procurement in 15 provinces [3][4] Strategic Focus and Market Position - Wanyi Technology positions itself in the mid-to-high-end market, benchmarking against international advanced products through technological innovation and performance enhancement, particularly in the gas analysis instrument market [4] - The company is increasing R&D investment, especially in liquid chromatography, to meet the growing domestic demand for localized alternatives in the analytical instrument market due to geopolitical influences [2][16] Semiconductor Sector Developments - The helium mass spectrometer is widely used in semiconductor manufacturing processes, including single crystal furnace pipelines, CVD, PVD, and plasma etching [12] - The company is developing gas analyzers for monitoring residual gas components during CVD and PVD processes to ensure chip quality [12] - Domestic companies like Changxin Storage and Yangtze Memory Technologies are increasingly adopting domestic equipment, achieving over 50% localization in manufacturing data collection [14] Nuclear Fusion Sector Contributions - Wanyi Technology provides high-precision vacuum leak detection solutions critical for the construction of nuclear fusion devices, with helium mass spectrometers being a core product [5][8] - The company occupies approximately 2%-3% of the cost structure in nuclear fusion reactors, contributing to various key systems including vacuum, raw material, thermal management, and measurement systems [8][10] - The company is actively involved in the Hefei Fusion Industry Alliance, enhancing its role as a key supplier in the nuclear fusion sector [10][11] Medical Device Market Insights - The ultrasonic scalpel market is estimated to be around 5-6 billion yuan, with a significant reliance on imports. Wanyi Technology aims to capture market share by offering competitively priced products [24] - The blood dialysis equipment market is projected to reach 10 billion yuan by 2025-2026, with the company expecting to launch its product by the end of 2026 [25][26] R&D and Future Outlook - Wanyi Technology maintains a high R&D investment, allocating about 20% of its revenue annually to R&D, with plans to stabilize this at around 15% in the future [27] - The company is optimistic about its prospects in the laboratory precision instrument sector, supported by favorable national policies and increasing domestic demand [23] Sales Strategy Adjustments - The company has shifted its sales model from relying on agents to a direct sales approach, enhancing customer engagement and improving gross margins [18] Conclusion - Wanyi Technology is strategically positioned to leverage its technological advancements and market opportunities across various sectors, including semiconductors, nuclear fusion, and medical devices, while maintaining a strong focus on R&D and market localization efforts [30]

核查意见 安徽天禾律师事务所 关于安徽皖仪科技股份有限公司 差异化分红事项的 核查意见 致：安徽皖仪科技股份有限公司 依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》(以下简称"《回购指引》")等法律、法规 和其他规范性文件以及《安徽皖仪科技股份有限公司章程》(以下简称"《公 司章程》")的有关规定，安徽天禾律师事务所接受安徽皖仪科技股份有限 公司（以下简称"公司"）的委托，就公司 2024 年度利润分配所涉及的差 异化权益分派(以下简称"本次差异化权益分派")相关事项出具本核查意 见。 为出具本核查意见，本所及本所律师审查了公司提供的本次差异化权 益分派的相关文件、查阅了公司公告。本所律师依据本核查意见出具日以 前已经发生或存在的事实并基于对现行法律、法规的理解发表核查意见。 本核查意见仅就本次差异化权益分派所涉及到的法律问题发表意见， 并不对有关会计、审计、验资等专业事项和报告发表意见。本核查意见中 对有关审计报告、验资报告中某些数据和结论的引述(如有)，并不意味着 本所对这些数据、 ...

证券代码：688600 证券简称：皖仪科技 公告编号：2025-052 安徽皖仪科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.10元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/20 | 2025/6/23 | 2025/6/23 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经安徽皖仪科技股份有限公司（以下简称"公司"）2025 年 5 月 19 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户中的股份除外）。 根据中国证监会《上市公司股份回购规则》、《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》等有关规定，公司回购 ...

证券代码：688600 证券简称：皖仪科技 公告编号：2025-051 安徽皖仪科技股份有限公司 关于完成董事会换届选举暨聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 安徽皖仪科技股份有限公司（以下简称"公司"或"皖仪科技"）于 2025 年 6 月 11 日召开 2025年第三次临时股东大会，选举产生了第六届董事会非独立 董事及独立董事，与公司于 2025 年 5 月 26 日召开的职工代表大会选举产生的 1 名职工董事夏明先生共同组成公司第六届董事会。 2025 年 6 月 11 日，公司召开第六届董事会第一次会议，选举产生了董事长、 董事会专门委员会委员，并聘任高级管理人员。现将相关情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 6 月 11 日，公司召开 2025 年第三次临时股东大会，本次股东大会 采用累积投票制方式选举臧牧先生、黄文平先生为第六届董事会非独立董事，选 举李维诗先生、罗彪先生、刘长宽先生为第六届董事会独立董事。本次股东大会 选举产生的 2 名非独 ...

证券代码：688600 证券简称：皖仪科技 公告编号：2025-050 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 11 日 （二） 股东大会召开的地点：安徽省合肥市高新技术产业开发区文曲路 8 号 办 公楼公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 27 | | --- | --- | | 普通股股东人数 | 27 | | 2、出席会议的股东所持有的表决权数量 | 63,774,131 | | 普通股股东所持有表决权数量 | 63,774,131 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 50.8880 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 50.8880 | 注：上述出席会议的股东所持有表决权数量占公司表决权数量的比例，已剔除公司已回购的 股份。 安徽皖仪科技股份有限公司 2025年 ...

法律意见书 安徽天禾律师事务所 关于安徽皖仪科技股份有限公司 2025 年第三次临时股东大会的 法律意见书 致：安徽皖仪科技股份有限公司 依据《中华人民共和国证券法》（以下简称"《证券法》"）、《中 华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会 规则》和《安徽皖仪科技股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，安徽天禾律师事务所接受安徽皖仪科技股份有限公司（以下 简称"公司"）的委托，指派吴波、叶慧慧两位律师（以下简称"本所律 师"）就公司于 2025 年 6 月 11 日召开的 2025 年第三次临时股东大会（以 下简称"本次股东大会"）出具本法律意见书。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责精神， 参与了本次股东大会，并对公司提供的有关文件和事实进行了核查和验证， 现出具法律意见如下： 一、本次股东大会的召集程序 本次股东大会由公司董事会召集。公司董事会于 2025 年 5 月 27 日在 上海证券交易所网站（www.sse.com.cn）、《上海证券报》《证券时报》 《证券日报》及巨潮资讯网（www.cninfo.com.cn）上发布了召开本次股东 ...